Commitment to spend, operational expenses, initial lease term Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term Payments as a percentage of net sales Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Interest expense recognized Interest Expense, Other Long-Term Debt Related-Party Debt Related-Party Agreements Related Party Transactions Disclosure [Text Block] Remaining authorized repurchase amount Share Repurchase Program, Remaining Authorized, Amount Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Cover [Abstract] Cover [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Net change in cash and cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Summary of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Patents Legal Costs, Policy [Policy Text Block] Trading Symbol Trading Symbol Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest ATM Offering Program At The Market Offering Program [Member] At-The-Market offering program. Non-NEOs Non-NEOs [Member] Prepaid research and development costs Prepaid Research And Development Costs Prepaid Research And Development Costs Summary of Interest and Investment Income , Net Interest and Other Income [Table Text Block] 2015 Equity Incentive Plan Two Thousand Fifteen Equity Incentive Plan [Member] Two thousand fifteen equity incentive plan. Allowances for prompt payment discounts, product returns and chargebacks Accounts Receivable, Allowance for Credit Loss, Current 2025 (excluding the six months ended June 30, 2025) Lessee, Lease Liability, to be Paid, Remainder of Fiscal Year Lessee, Lease Liability, to be Paid, Remainder of Fiscal Year Thereafter Lessee, Lease Liability, to be Paid, After Year Five Lessee, Lease Liability, to be Paid, After Year Five Payment to acquire other equity security Payments to Acquire Equity Securities, FV-NI Accounts receivable Increase (Decrease) in Accounts Receivable Property, Plant and Equipment, Impairment Property, Plant and Equipment, Impairment [Policy Text Block] Basic and Diluted Net Loss per Share of Common Stock Earnings Per Share, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] 2015 Share Repurchase Plan Two Thousand Fifteen Share Repurchase Plan [Member] 2015 share repurchase plan. Proceeds from exercises of stock options Proceeds from stock options exercised Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Purchase agreement milestone, received Purchase Agreement Milestone, Received Purchase Agreement Milestone, Received Change in fair value of derivative liabilities Derivative, Gain (Loss) on Derivative, Net July 2025 Warrant July 2025 Warrant [Member] July 2025 Warrant Lease-related payables Lease Related Payables Lease-related payables. Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Proceeds from sales of marketable debt securities Proceeds from Sale and Maturity of Marketable Securities Warrant Liabilities Warrant Liability [Text Block] Warrant Liability Revenue from Contract with Customer [Abstract] Salzman Litigation Salzman Litigation [Member] Salzman Litigation Plan Name Plan Name [Domain] Sale of stock (in dollars per share) Sale of Stock, Price Per Share U.S. UNITED STATES Other assets Other Assets, Noncurrent Leases [Abstract] Leases [Abstract] Accrued research and development costs Accrued Research And Development Costs Accrued research and development costs. Gross carrying amount Finite-Lived Intangible Assets, Gross Stock Options, Other Exercise of Stock Options [Member] Exercise of Stock Options Payments for legal settlement expenses Payments for Legal Settlements Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Measurement Frequency Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted average remaining lease term, finance leases Finance Lease, Weighted Average Remaining Lease Term Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Transaction Type Transaction Type [Axis] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Accrued expenses and other liabilities Accrued Liabilities, Current Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Asset Acquisition [Axis] Asset Acquisition [Axis] Related-party convertible notes Related Party, Convertible Notes [Member] Related Party, Convertible Notes Accrued sales costs Accrued Marketing Costs, Current Shared Services Agreement Shared Services Agreement [Member] Shared services agreement. Payable and Accruals [Axis] Payable and Accruals [Axis] Payable and Accruals Weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Goodwill, net Business combination, goodwill Goodwill Fourth Largest Customer Fourth Largest Customer [Member] Fourth Largest Customer Net share settlement for RSUs vesting Payment, Tax Withholding, Share-Based Payment Arrangement Other comprehensive income (loss), net of income taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Inventories Inventory Disclosure [Text Block] Income Tax [Table] Income Tax [Table] Income tax. Schedule Of Available For Sale Securities [Table] Debt Securities, Available-for-Sale [Table] Outstanding stock options Stock options Share-Based Payment Arrangement, Option [Member] Depreciation expense related to property, plant and equipment Depreciation 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss attributable to ImmunityBio common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Weighted average discount rate, finance leases Finance Lease, Weighted Average Discount Rate, Percent 2026 Finance Lease, Liability, to be Paid, Year One Award Type Award Type [Axis] Net loss per ImmunityBio common share – basic Earnings Per Share, Basic [Abstract] Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Work-in-progress Inventory, Work in Process, Net of Reserves Summary of Supplemental Balance Sheet Information Related to Leases Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Related-party convertible note payable at fair value Convertible Debt [Member] Total indefinite-lived assets, net Indefinite-Lived Intangible Assets, Net of Accumulated Impairment Indefinite-Lived Intangible Assets, Net of Accumulated Impairment 12 to 18 Months From Closing Date Period Two [Member] Period Two Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign Currencies Foreign Currency Transactions and Translations Policy [Policy Text Block] GlobeImmune, Inc. GlobeImmune, Inc. [Member] GlobeImmune, Inc. Expiration Date Trading Arrangement Expiration Date Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Litigation [Line Items] Litigation [Line Items] Litigation. Operating lease liabilities Operating lease liabilities (including amounts with related parties) Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Summary of RSU Activity under Equity Plans Nonvested Restricted Stock Shares Activity [Table Text Block] Change in fair value of derivative liabilities Change in Fair Value of Derivative Liabilities Change in Fair Value of Derivative Liabilities Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total lease assets (including amounts with related parties) Lease, Right-Of-Use Asset Lease, Right-Of-Use Asset $505 Million Promissory Note, December 2023 $505 Million Promissory Note, December 2023 [Member] $505 Million Promissory Note, December 2023 Contingent consideration Contingent Consideration [Member] Contingent Consideration Equipment Equipment [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Prepaid insurance Prepaid Insurance Gross property, plant and equipment Property, Plant and Equipment, Gross Exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development expense Research and development Research and Development Expense [Member] Long-Term Debt, Fair Value Disclosure [Roll Forward] Long-Term Debt, Fair Value Disclosure [Roll Forward] Long-Term Debt, Fair Value Disclosure Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average number of common shares used in computing net loss per share – diluted (in shares) Denominator for net loss per ImmunityBio common share - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total ImmunityBio stockholders’ deficit Equity, Attributable to Parent Stock option liability, measurement input Derivative Liability, Measurement Input Transactions with Related Parties Related Party Transactions, Policy [Policy Text Block] Related Party Transactions, Policy Litigation Case [Axis] Litigation Case [Axis] Software Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Selling, general and administrative Selling, general and administrative (including amounts with related parties) Selling, General and Administrative Expense Product revenue, net Product [Member] Stock reserved for issuance under award plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock Sale of Stock [Domain] $200 Million September 2023 Promissory Note $200 Million September 2023 Promissory Note [Member] $200 Million September 2023 Promissory Note Document Fiscal Period Focus Document Fiscal Period Focus Number of square foot of facility leased Number Of Square Feet Of Facility Leased Number of square feet of facility leased. All Executive Categories All Executive Categories [Member] Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Equity securities Equity Securities [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS Assets [Abstract] Total other comprehensive (loss) income Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Third Largest Customer Third Largest Customer [Member] Third Largest Customer Cloud Computing Arrangement Internal Use Software, Policy [Policy Text Block] Non-related Party Nonrelated Party [Member] Cash and cash equivalents, and restricted cash, beginning of period Cash and cash equivalents, and restricted cash, end of period Cash and cash equivalents, and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Amortized cost Debt Securities, Available-for-Sale, Amortized Cost September 2019 Lease September Twenty Nineteen Lease [Member] September twenty nineteen lease. Summary of Future Amortization Expense Associated with Definite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Subsequent Event [Table] Subsequent Event [Table] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Net carrying amount Finite-Lived Intangible Assets, Net Furniture & fixtures Furniture and Fixtures [Member] Antidilutive Securities Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Schedule of Valuation Assumptions Under Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Advances to noncontrolling interest holders Related Party Transaction, Amounts of Transaction NCSC NCSC [Member] NCSC. Total lease expense Lease, Cost Statistical Measurement Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income taxes and noncontrolling interests Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Name Outstanding Recovery, Individual Name Initial term of supply agreement Supply Agreement, Term Of Contract Supply Agreement, Term Of Contract Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Variable lease costs Variable Lease, Cost Goodwill impairment Goodwill, Impairment Loss Summary of Securities Excluded from the Computation of Potentially Dilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Change in fair value of related-party convertible note related to instrument-specific credit risk Increase (Decrease) in Fair Value, Long-Term Debt, Credit Risk Increase (Decrease) in Fair Value, Long-Term Debt, Credit Risk Investment, Name [Axis] Investment, Name [Axis] Forecast Forecast [Member] Net loss per ImmunityBio common share - diluted (in dollars per share) Earnings Per Share, Diluted IPR&D, gross Indefinite Lived Intangible Assets, Gross, Excluding Goodwill Indefinite Lived Intangible Assets, Gross, Excluding Goodwill Research And Development Arrangements With Federal Government [Table] Research And Development Arrangements With Federal Government [Table] Research And Development Arrangements With Federal Government [Table] Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Ownership Ownership [Axis] Change in fair value of warrant liabilities Change in fair value of warrant liabilities Fair Value Adjustment of Warrants Customer [Axis] Customer [Axis] Outstanding related-party warrants Related Party Warrants [Member] Related Party Warrants 2028 Lessee, Lease Liability, to be Paid, Year Three Lessee, Lease Liability, to be Paid, Year Three Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Reimbursements Reimbursements [Member] Reimbursements. Prepaid equipment maintenance Prepaid Equipment Maintenance Prepaid equipment maintenance. Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income tax expense Income tax expense Income tax expense Income Tax Expense (Benefit) Other income (expense), net Nonoperating Income (Expense) [Abstract] Forfeited/expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Promissory Note Promissory Notes Payable [Member] Promissory Notes Payable Estimated benefit at grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Estimated Benefit At Grant Date Fair Value Share based compensation arrangement by share based payment award estimated benefit at grant date fair value. Weighted-average period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Option Period [Domain] Option Period [Domain] Option Period [Domain] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Interest expense – related party Interest Expense, Operating and Nonoperating Business Acquisition [Line Items] Business Acquisition [Line Items] Equity Method of Accounting Equity Method Investments [Policy Text Block] Other Other Operating Activities, Cash Flow Statement All Adjustments to Compensation All Adjustments to Compensation [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Cumulative purchaser payments Revenue Interest Purchase Agreement, Cumulative Purchaser Payments Revenue Interest Purchase Agreement, Cumulative Purchaser Payments Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity Legal Entity [Axis] Favorable Leasehold Rights Off-Market Favorable Lease [Member] Scenario [Domain] Scenario [Domain] Related Party Transaction Related Party Transaction [Axis] Prepaid software license fees Prepaid Software License Fees Prepaid software license fees. Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Annual lease payment Lease, Operating Lease, Annual Lease Payment Lease, Operating Lease, Annual Lease Payment Financial Instruments Financial Instruments [Domain] Nonvested, beginning balance (in dollars per share) Nonvested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] 2027 Lessee, Lease Liability, to be Paid, Year Two Lessee, Lease Liability, to be Paid, Year Two Stock Purchase And Option Agreement Stock Purchase And Option Agreement [Member] Stock Purchase And Option Agreement Equipment, depreciation, and facility costs Research and Development Expense, Internal, Equipment, Depreciation, and Facility Costs Research and Development Expense, Internal, Equipment, Depreciation, and Facility Costs Contractual annual interest rate on advances to noncontrolling interests Related Party Transaction, Rate Restatement Determination Date Restatement Determination Date Weighted average remaining contractual life (in years) Debt Securities, Available-for-Sale, Term Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Common Control Transactions Combination of Entities under Common Control, Policy [Policy Text Block] Summary of Available-for-Sale Marketable Debt Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets, net Operating lease assets (including amounts with related parties) Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Stock Repurchases Stock Repurchase Program, Policy [Policy Text Block] Stock Repurchase Program, Policy Property, Plant and Equipment [Abstract] Lease Contractual Term Lease Contractual Term [Axis] Financial Statement Details Additional Financial Information Disclosure [Text Block] Subsequent Event Subsequent Event [Member] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Various Various [Member] Various. Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Interest and investment income, net Interest and investment income, net Gain (Loss) on Investments Change in Fair Value of Derivative Liabilities Schedule of Derivative Liabilities at Fair Value [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: Interest Lessee, Lease Liability, Undiscounted Excess Amount Lessee, Lease Liability, Undiscounted Excess Amount Segments [Domain] Segments [Domain] Revenue Interest Purchase Agreement [Abstract] Revenue Interest Purchase Agreement Change in fair value of related-party convertible note Change in fair value of related-party convertible note Fair Value, Option, Changes in Fair Value, Gain (Loss) PEO PEO [Member] Name Trading Arrangement, Individual Name Total internal research and development expense Research and Development Expense, Internal Research and Development Expense, Internal Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other income (expense), net Other Nonoperating Income (Expense) [Abstract] Expected volatility Measurement Input, Volatility Measurement Input, Price Volatility [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Amyris Joint Venture Amyris Joint Venture [Member] Amyris Joint Venture Local Phone Number Local Phone Number Goodwill and intangible assets, gross Intangible Assets, Gross (Excluding Goodwill) Maximum milestone payment due if certain conditions are met Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Investment interest rate Investment Interest Rate Operating expenses Total operating costs and expenses Operating Expenses Commitment to hire, number of employees, first five years Leasehold Interest, Commitment to Hire, Number of Employees, First Five Years Leasehold Interest, Commitment to Hire, Number of Employees, First Five Years Asset Acquisition [Line Items] Asset Acquisition [Line Items] Convertible Note Convertible Notes Payable [Member] Weighted- Average Remaining Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Commitment to spend, operational expenses, renewal lease term Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Income Statement Location Statement of Income Location, Balance [Axis] Vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Debt Disclosure [Abstract] Common Stock Common Stock [Member] Annual minimum licensing payment Collaboration Agreements, Annual Minimum Licensing Payment Collaboration Agreements, Annual Minimum Licensing Payment Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule Of Business Acquisitions By Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Changes in Carrying Amount of Warrant Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] NantWorks NantWorks, LLC [Member] NantWorks, LLC Segment Reporting [Abstract] Commissions and offering costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Intangible Assets, Net Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Net share settlement for RSUs vesting (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Statement of Inventories Schedule of Inventory, Current [Table Text Block] Second Largest Customer Second Largest Customer [Member] Second Largest Customer Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stockholders’ Deficit Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument Financial Instrument [Axis] Segment Information Segment Reporting Disclosure [Text Block] Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Revenue interest payment Debt Instrument, Periodic Payment, Interest Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Risk-free interest rate Measurement Input, Risk-Free Rate Measurement Input, Risk Free Interest Rate [Member] Convertible note receivable Convertible Note Receivable Non Current Convertible note receivable, non-current. Title Trading Arrangement, Individual Title Consolidated Entities Consolidated Entities [Axis] NantCancerStemCell NantCancerStemCell [Member] NCSC. Unrecognized tax benefit Unrecognized Tax Benefits Less: Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest City Area Code City Area Code Accrued Rebates, Co-payment Assistance and Other Fees Accrued Rebates, Co-payment Assistance and Other Fees [Member] Accrued Rebates, Co-payment Assistance and Other Fees Current liabilities: Liabilities, Current [Abstract] Total future minimum lease payments Lessee, Lease Liability, to be Paid Lessee, Lease Liability, to be Paid Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stock option purchase liability Stock Option Purchase Liability [Member] Stock Option Purchase Liability Summary of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Acquisition of Workforce Acquisition of Workforce [Member] Acquisition of Workforce [Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Equity Method Investment, Nonconsolidated Investee Equity Method Investment, Nonconsolidated Investee, Other [Member] Schedule of Unobservable Assumptions Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Weighted- Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Dunkirk Facility Dunkirk Facility [Member] Dunkirk Facility Subsequent Event Type [Axis] Subsequent Event Type [Axis] Expected term Measurement Input, Expected Term [Member] Financial Instruments Investment [Text Block] Equity [Abstract] Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Repurchase of common stock, shares (in shares) Stock Repurchased and Retired During Period, Shares Forfeited/expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Summary of Related-Party Debt Schedule of Related-Party Promissory Notes Table [Table Text Block] Schedule of related party notes payable. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Commitments for capital expenditures and open purchase orders Other Commitment, to be Paid, Remainder of Fiscal Year Inventories Increase (Decrease) in Inventories 2027 Long-Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Operating lease liabilities Present value of lease liabilities Operating Lease, Liability Maximum offering Sale Of Stock, Maximum Aggregate Offering Value Sale Of Stock, Maximum Aggregate Offering Value Total Lease Liability, Payments Due [Abstract] Lease Liability, Payments Due Underlying Securities Award Underlying Securities Amount Largest Customer Largest Customer [Member] Largest Customer Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] 2030 Finance Lease, Liability, to be Paid, Year Five Amendment Flag Amendment Flag 18 to 36 Months From Closing Date Period Three [Member] Period Three Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Subsequent Events [Abstract] Measurement input Debt Instrument, Measurement Input Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Revenue Interest Purchase Agreement Debt Disclosure [Text Block] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Face amount Debt Instrument, Face Amount Related Party Notes - Principal [Member] Related Party Notes - Principal [Member] Related Party Notes - Principal Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain] Percentage of annual increases of base rent Annual Percentage Increase To Base Rent Annual percentage increase to base rent. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Measurement Input, Market Yield Measurement Input, Market Yield [Member] Measurement Input, Market Yield Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Maximum number of shares that may be added to the 2025 Plan from the prior plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares That May be Carried Over to a Subsequent Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares That May be Carried Over to a Subsequent Plan Forfeited/canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Effect of exchange rate changes on cash and cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Gain (Loss) on debt extinguishment Gain (Loss) on Extinguishment of Debt Current Liabilities Other Current Liabilities [Member] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Useful life Property, Plant and Equipment, Useful Life Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Related-party convertible note payable, at fair value (Note 9 and Note 14) Convertible Notes Payable, Noncurrent Purchase price allocation Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] 2022 Collaborative Arrangement and Arrangement Other than Collaborative, Fee One [Member] Collaborative Arrangement and Arrangement Other than Collaborative, Fee One Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Principal payments of finance leases Financing cash flow from finance leases Finance Lease, Principal Payments Operating lease payments related to options to extend lease terms Operating Lease Payments Related To Options To Extend Lease Terms Operating lease payments related to options to extend lease terms. Net loss attributable to ImmunityBio common stockholders Net loss attributable to ImmunityBio common stockholders Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Assets Cost of sales Cost of Goods and Services Sold Change in fair value of related-party convertible note Increase (Decrease) in Fair Value, Long-Term Debt Increase (Decrease) in Fair Value, Long-Term Debt Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Other liabilities Other Liabilities, Noncurrent Options to extend number of terms Options To Extend Number Of Terms Options to extend number of terms. Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 11) Commitments and Contingencies Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Reclassification of net realized gains (losses) on available-for-sale securities included in net loss Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Termination Date Trading Arrangement Termination Date Description of Business Nature of Operations [Text Block] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Table] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Due to related parties Due To Related Parties [Member] Due to related parties. 2026 Long-Term Debt, Maturity, Year One Revenue interest purchase agreement, tiered revenue interest rate percentage Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage Schedule of Revenue by Geographic Region Revenue from External Customers by Geographic Areas [Table Text Block] Fair value of warrants Warrants Not Settleable in Cash, Fair Value Disclosure Debt Instrument [Axis] Debt Instrument [Axis] Amount Convertible Debt, Fair Value Disclosures Net loss attributable to ImmunityBio common stockholders Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Amortization of related-party notes discounts Amortization of Debt Discount (Premium) Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Research and Development Arrangements with Federal Government [Line Items] Research And Development Arrangements With Federal Government [Line Items] Research and development arrangements with the federal government. Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Consolidated Entities Consolidated Entities [Domain] Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Initial term of lease arrangement Lessee, Operating Lease, Term of Contract Name Forgone Recovery, Individual Name Transaction Transaction [Domain] Weighted average remaining lease term, operating leases Operating Lease, Weighted Average Remaining Lease Term Contingent Consideration by Type Contingent Consideration by Type [Axis] Change in fair value of related-party convertible note related to instrument-specific credit risk Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment Number of lease renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Non-cash interest items, net Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Transaction costs allocated to warrant liabilities Transaction Costs, Warrant Liability Transaction Costs, Warrant Liability Minimum net sales milestone for contingent value rights payable Minimum Net Sales Milestone Contingent Value Rights Obligation Minimum net sales milestone contingent value rights obligation. Advances To Related Party Advances To Related Party [Member] Advances To Related Party Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair value at issuance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Number of leases Number of Leases Number of Leases PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Warrant liabilities (Note 16) Warrants and Rights Outstanding Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable, Net Accounts Receivable [Member] Net loss attributable to noncontrolling interests, net of tax Net Income (Loss) Attributable to Noncontrolling Interest Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Document Quarterly Report Document Quarterly Report Litigation Case [Domain] Litigation Case [Domain] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Private Placement and At the Market Offerings Private Placement and At the Market Offerings [Member] Private Placement and At the Market Offerings [Member] Laboratory equipment Other Machinery and Equipment [Member] Top Four Customers Top Four Customers [Member] Top Four Customers Weighted-average number of common shares used in computing net loss per share – basic (in shares) Weighted-average number of common shares outstanding - basic (in shares) Weighted-average number of common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Related-Party Related and Nonrelated Parties [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] More than 12 months, Gross Unrealized Losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Total stockholders’ deficit Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Amortization of related-party notes discounts Amortization of Debt Issuance Costs and Discounts Licensing Agreement [Line Items] Licensing Agreement [Line Items] Licensing agreement. Accrued professional and service fees Accrued Professional Fees, Current Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Preclinical and Clinical Trial Accruals Preclinical and Clinical Trial Accruals, Policy [Policy Text Block] Preclinical and Clinical Trial Accruals, Policy Revenue Benchmark Revenue Benchmark [Member] Less than 12 months, Gross Unrealized Losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Entity Filer Category Entity Filer Category Registered Direct Offering Private Placement [Member] Expansion Premises Expansion Premises [Member] Amendment for expansion of premises, lease term. Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Statistical Measurement Statistical Measurement [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Summary of Information Regarding Leases Lease, Cost [Table Text Block] Long-Term Debt [Roll Forward] Long-Term Debt [Roll Forward] Long-Term Debt Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Basic and Diluted Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] 605 Nash, LLC Six Zero Five Nash, LLC [Member] Six Zero Five Nash, LLC Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income taxes Income Taxes Paid, Net Other Commitments [Line Items] Other Commitments [Line Items] Revenue Interest Purchase Agreement Revenue Interest Purchase Agreement [Member] Revenue Interest Purchase Agreement Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounting Policies [Line Items] Accounting Policies [Line Items] Accounting policies. Goodwill and Intangible Assets [Table] Goodwill and Intangible Assets [Table] Goodwill and Intangible Assets Initial measurement of warrants issued in connection with equity offerings accounted for as liabilities Issuance Of Warrants Issuance Of Warrants Operating lease liabilities Increase in operating lease liabilities Increase (Decrease) in Operating Lease Liability Proceeds from insurance claim Proceeds from Insurance Settlement, Operating Activities Goodwill and intangible assets, net Goodwill and intangible assets, net Intangible Assets, Net (Including Goodwill) License Agreement Terms License Agreement Terms [Member] Revenue decrease, gross-to-net accruals Revenue from Contract with Customer, Increase (Decrease) Related to Gross-to-Net Accruals Revenue from Contract with Customer, Increase (Decrease) Related to Gross-to-Net Accruals Other Performance Measure, Amount Other Performance Measure, Amount 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three Lease Arrangements Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding AAHI AAHI [Member] AAHI Operating lease costs Operating Lease, Cost Due from related parties Other Receivables, Net, Current Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement [Member] Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Common stock reserved for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities, less current portion Operating Lease, Liability, Noncurrent Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Interest receivable Interest Receivable Other revenues Product and Service, Other [Member] Warrants, expiration term Warrants and Rights Outstanding, Term Initial Premises Initial Premises [Member] Initial Premises. Entity Tax Identification Number Entity Tax Identification Number Investment accretion income, net Investment Income, Net, Amortization of Discount and Premium Selling, general and administrative Selling, General and Administrative Expenses [Member] Sale of stock issued in transaction Sale of Stock, Consideration Received on Transaction Number of warrants exercised (in shares) Class of Warrant or Right, Exercised Class of Warrant or Right, Exercised U.S. Treasury securities US Treasury Securities [Member] Plan Name Plan Name [Axis] Thereafter Finance Lease, Liability, to be Paid, after Year Five Altor Stockholders Altor Stockholders [Member] Altor Stockholders Equity Components [Axis] Equity Components Equity Components [Axis] Total future minimum lease payments Finance Lease, Liability, to be Paid Other Other Assets, Current Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Fair Value Debt Securities, Available-for-Sale Accounts Receivable, Net Accounts Receivable [Policy Text Block] 2029 Lessee, Lease Liability, to be Paid, Year Four Lessee, Lease Liability, to be Paid, Year Four Total operating costs and expenses Costs and Expenses $505 Million Promissory Note, December 2023, Tranche 2 $505 Million Promissory Note, December 2023, Tranche 2 [Member] $505 Million Promissory Note, December 2023, Tranche 2 Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Brink Biologics, Inc. Brink Biologics, Inc. [Member] Brink Biologics, Inc. 2025 Equity Incentive Plan Equity Incentive Plan, 2025 [Member] Equity Incentive Plan, 2025 Outstanding, beginning balance Outstanding, ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Net loss per ImmunityBio common share – diluted Earnings Per Share, Diluted [Abstract] Geographical Geographical [Axis] Proceeds from maturities of marketable debt securities, available-for-sale Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale 2030 Lessee, Operating Lease, Liability, to be Paid, Year Five Purchase agreement milestone Purchase Agreement Milestone Purchase Agreement Milestone Cash Flow Operating Activities Lessee [Abstract] Cash Flow, Operating Activities, Lessee [Abstract] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Number of warrants issued (in shares) Number of shares available for purchase (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Loss Contingency Accrual Loss Contingency Accrual Schedule Of Available For Sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Lease expense Operating Lease, Expense Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Accrued bonus Accrued Bonuses, Current Cost of Sales Cost of Goods and Service [Policy Text Block] Accretion of discounts on marketable debt securities Accretion (Amortization) of Discounts and Premiums, Investments Altor BioScience Corporation Altor BioScience, LLC [Member] Altor BioScience Corporation. Current assets: Assets, Current [Abstract] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Treasury stock, common shares (in shares) Treasury Stock, Common, Shares Riptide Bioscience, Inc. Riptide Bioscience, Inc. [Member] Riptide Bioscience, Inc. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Short-term lease costs Short-Term Lease, Cost Potential contingent value rights to be earned Contingent Value Rights Obligations Contingent value rights obligations. Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Marketable securities Marketable Securities, Current Ownership percentage acquired Percentage Of Wholly Owned Subsidiary Percentage of wholly-owned subsidiary. Outstanding third-party warrants Warrant liabilities Warrants Warrant [Member] Security Exchange Name Security Exchange Name Interest rate spread Debt Instrument, Basis Spread on Variable Rate Related Party Transaction Related Party Transaction [Domain] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Prepaid rent Prepaid Rent Collaboration and License Agreements and Acquisition Research, Development, and Computer Software Disclosure [Text Block] Number of Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Lease Contractual Term Lease Contractual Term [Domain] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Other commitments Other Commitment Research and development Research and development expense Total research and development expense (including amounts with related parties) Research and Development Expense Net realized (losses) gains on investments Realized Investment Gains (Losses) Right-of-use assets obtained in exchange for finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Goodwill and Intangible Assets Disclosure [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Entity Entity [Domain] Later Than 36 Months from Closing Date Period Four [Member] Period Four Concentration risk, percentage Concentration Risk, Percentage IT equipment Computer Equipment [Member] VivaBioCell VivaBioCell [Member] VivaBioCell. Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Duley Road, LLC Duley Road, LLC [Member] Duley Road, LLC. Revenue interest liability (Note 13) Revenue interest liability, beginning balance Revenue interest liability, ending balance Secured Long-Term Debt, Noncurrent Tiered Payments [Domain] Tiered Payments [Domain] Tiered Payments [Domain] Europe Europe [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Prepaid services Prepaid Services Prepaid services. Office equipment Office Equipment1 [Member] Office Equipment1 2025 (excluding the six months ended June 30, 2025) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Related-Party Related Party [Member] Optional extended lease term Extended lease term Lessee, Operating Lease, Renewal Term Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Payable and Accruals [Domain] Payable and Accruals [Domain] Payable and Accruals [Domain] Accrued compensation Accrued Salaries, Current Property, Plant and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Percentage of ownership interest Subsidiary, Ownership Percentage, Parent More than 12 months, Estimated Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Carrying value of debt Total Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Income Tax [Line Items] Income Tax [Line Items] Income tax. Proceeds from exercises of warrants Proceeds from Warrant Exercises Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Vesting of restricted stock units (RSUs) (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Advances to support operations Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures 2028 Finance Lease, Liability, to be Paid, Year Three Fair Value Option Election Convertible Notes, Fair Value Option Election [Policy Text Block] Convertible Notes, Fair Value Option Election Vested (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Duley Road, LLC Duley Road [Member] Duley Road. Total ImmunityBio Stockholders’ Deficit Parent [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate July 2023 Warrants July 2023 Warrants [Member] July 2023 Warrants IPR&D, Net Indefinite-Lived Intangible Assets (Excluding Goodwill) Amortization expense Amortization of Intangible Assets Deferred revenue Contract with Customer, Liability Foreign Jurisdictions Non-US [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Leasehold improvements Leasehold Improvements [Member] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Accrued expenses and other liabilities Accrued rebates, co-payment assistance and other fees Accounts Payable and Other Accrued Liabilities, Current Revenue interest purchase agreement, payment received percentage Revenue Interest Purchase Agreement, Payment Received Percentage Revenue Interest Purchase Agreement, Payment Received Percentage PEO Name PEO Name Number of warrants outstanding (in shares) Number of warrants outstanding (in shares) Class of Warrant or Right, Outstanding Percentage of sales agent commission Percentage Of Sales Agent Commission Percentage Of Sales Agent Commission Award Type Award Type [Domain] Exercise of warrants Stock Issued During Period, Value, Warrants Exercised Stock Issued During Period, Value, Warrants Exercised Accrued revenue interest payment Accrued Revenue Interest Payment Accrued Revenue Interest Payment Proceeds from the RIPA, net of issuance costs Proceeds from Issuance of Secured Debt Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Summary of Goodwill and Intangible Assets, Net Schedule of Intangible Assets and Goodwill [Table Text Block] Non-PEO NEO Non-PEO NEO [Member] Weighted average life (in years) Finite-Lived Intangible Asset, Useful Life Accrued preclinical and clinical trial costs Accrued Preclinical And Clinical Trial Costs Accrued preclinical and clinical trial costs. Additional Paid-in Capital Additional Paid-in Capital [Member] Finance Lease, Liability, Noncurrent Finance Lease, Liability, Noncurrent Class Of Stock [Line Items] Class of Stock [Line Items] Periodic license payments, annual Collaboration Agreements, Periodic License Payments Collaboration Agreements, Periodic License Payments RIPA derivative liability Derivative Liabilities [Member] Derivative Liabilities Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other research and development costs Research and Development Expense, Internal, Other Costs Research and Development Expense, Internal, Other Costs Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] 2029 Finance Lease, Liability, to be Paid, Year Four Accumulated amortization Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Research and Development [Abstract] Research and Development [Abstract] Non-cash lease expense related to operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current 2026 Lessee, Lease Liability, to be Paid, Year One Lessee, Lease Liability, to be Paid, Year One Financial Statement Details [Table] Financial Statement Details [Table] Financial Statement Details [Table] Valuation Technique, Binomial Lattice Model Valuation Technique, Binomial Lattice Model [Member] Valuation Technique, Binomial Lattice Model Number of operating segments Number of Operating Segments Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Change in Fair Value of Stock Option Purchase Liability Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Litigation [Table] Litigation [Table] Litigation. Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Contingent Consideration Type Contingent Consideration Type [Domain] Aggregate intrinsic value, vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Unpaid offering costs included in accounts payable, and accrued expenses and other liabilities Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses Unpaid offering costs included in accounts payable and accrued expenses. Numerator for net loss per ImmunityBio common share – diluted Net Income (Loss) Available to Common Stockholders, Diluted Required purchase price, as a percent Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price Total other expense, net Total other expense, net Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Loss from operations Operating Income (Loss) Number of Reportable Segments Number of Reportable Segments 2025 (excluding the six months ended June 30, 2025) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Total liabilities and stockholders’ deficit Liabilities and Equity Deemed dividends Dividends Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] 2030 Lessee, Lease Liability, to be Paid, Year Five Lessee, Lease Liability, to be Paid, Year Five Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Percent of common stock outstanding after option exercise, maximum Sale of Stock, Percentage of Ownership after Transaction Marketable Securities and Other Investments Marketable Securities, Policy [Policy Text Block] Warrants Warrants [Policy Text Block] Warrants 2027 Finance Lease, Liability, to be Paid, Year Two Non-cash interest expense related to revenue interest liability Interest Expense, Nonoperating, Secured Debt, Net Interest Expense, Nonoperating, Secured Debt, Net Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Total indefinite-lived assets, gross Indefinite Lived Intangible Assets, Gross, Including Goodwill Indefinite Lived Intangible Assets, Gross, Including Goodwill Unrealized losses from equity securities Debt and Equity Securities, Unrealized Gain (Loss) Summary of Future Contractual Obligations of Related Party Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis] Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule April 2025 Warrants April 2025 Warrants [Member] April 2025 Warrants Measurement Input Type [Axis] Measurement Input Type [Axis] Individual: Individual [Axis] Net share settlement for RSUs vesting Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories Inventories Inventory, Net Contingent Value Rights Payable, Sales Milestone Contingent Value Rights Obligation, Sales Milestone [Member] Contingent value rights obligation before December 31, 2026. Product and Service [Axis] Product and Service [Axis] February 2023 Shelf Registration Statement February 2023 Shelf Registration Statement [Member] February 2023 Shelf Registration Statement Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Sponsored Research Agreement Sponsored Research Agreement [Member] Sponsored research agreement. Summary of Outstanding Balances of Related-Party Agreements Schedule of Related Party Transactions [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Operating costs and expenses Operating Expenses [Abstract] Business combination, fair value of net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Schedule of Estimated Useful Lives of Property, Plant and Equipment Summary of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Business combination, consideration transferred Business Combination, Consideration Transferred Fair value, beginning of period Fair value, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Minimum Minimum Minimum [Member] Adoption Date Trading Arrangement Adoption Date Measurement input Warrants and Rights Outstanding, Measurement Input Related Party Transactions [Abstract] Related Party Transactions [Abstract] Government funding for leasehold build-out Leasehold Interest, Government Funding Available Leasehold Interest, Government Funding Available December 2022 Warrants [Member] December 2022 Warrants [Member] December 2022 Warrants Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Summary of Prepaid Expenses and Other Current Assets Schedule of Other Current Assets [Table Text Block] Principal Amount Long-Term Debt, Gross Exercise Price Award Exercise Price Interest expense related to revenue interest liability Interest Expense, Other Asset Acquisition [Table] Asset Acquisition [Table] State Of New York State Of New York [Member] State Of New York 420 Nash, LLC Four Two Zero Nash, LLC [Member] Four Two Zero Nash, LLC Acquisition of Workforce and Office Equipment Acquisition of Workforce and Office Equipment [Member] Acquisition of Workforce and Office Equipment Arrangement Duration Trading Arrangement Duration Lease Arrangements Lessee, Finance Leases [Text Block] Goodwill and Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Stockholders’ deficit: Equity, Attributable to Parent [Abstract] Less than 12 months, Estimated Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months February 2023 Warrants February 2023 Warrants [Member] February 2023 Warrants External research and development expense (including amounts with related parties) Research and Development Expense, External Research and Development Expense, External Interest income Interest and Other Income Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Interest Payments Related Party Notes - Interest [Member] Related Party Notes - Interest Accounts payable Increase (Decrease) in Accounts Payable, Trade Immuno-Oncology Clinic, Inc. Immuno-Oncology Clinic [Member] Immuno-Oncology Clinic. Present value of lease liabilities Finance Lease, Liability 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Exercise of warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised Stock Issued During Period, Shares, Warrants Exercised Building Building [Member] Option Period [Axis] Option Period [Axis] Option Period Due to and due from related parties, net Increase Decrease In Due To Related Parties Current And Non Current Increase decrease in due to related parties current and non current. Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Other expense, net Other expense, net Other Nonoperating Income (Expense) Base rent - monthly Monthly Base Rent Monthly base rent. Goodwill, gross Goodwill, Gross Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Collaboration agreements, milestone payment Collaboration Agreements, Milestone Payment, Payable Amount Milestone payment amount. Tiered Payments [Axis] Tiered Payments [Axis] Tiered Payments Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Other assets Increase (Decrease) in Other Noncurrent Assets Unrecognized compensation cost related to non-vested stock options Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount 2025 (excluding the three months ended March 31, 2025) Long-Term Debt, Maturity, Remainder of Fiscal Year Available for future stock issuance Sale of Stock, Amount Available For Future Stock Issuance Sale of Stock, Amount Available For Future Stock Issuance ATM, amount available for future issuances Sale of Stock Offering, Amount Available for Future Issuance Sale of Stock Offering, Amount Available for Future Issuance 605 Doug St, LLC Six Zero Five Doug St, LLC [Member] Six Zero Five Doug St, LLC IPR&D IPR&D [Member] IPR&D Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Related Party Related and Nonrelated Parties [Domain] Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value. Immuno-Oncology Clinic, Inc. Immuno-Oncology Clinic, Inc [Member] Immuno Oncology Clinic Inc. Liability Class Liability Class [Axis] Amyris, Inc. Amyris, Inc. [Member] Amyris, Inc. Unrealized (losses) gains on marketable debt securities, net Unrealized Gain (Loss) on Investments Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Number of securities in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Offering costs Payment of offering costs Payments of Stock Issuance Costs Total lease liabilities (including amounts with related parties) Lessee, Lease Liability Lessee, Lease Liability Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Financial Statement Details [Abstract] Financial Statement Details [Abstract] Financial statement details. Measure: Measure [Axis] Asset Class Asset Class [Domain] Issuance of common stock "at the market" offering, net of commissions and offering costs (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Liabilities measured at fair value Liabilities, Fair Value Disclosure Warrants Warrants [Member] Warrants. Licensing Agreement [Table] Licensing Agreement [Table] Licensing agreement. Lessee Lease Description [Table] Lessee, Lease, Description [Table] Upfront payment received Upfront Payment Received Upfront Payment Received Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Summary of Accrued Expenses and Other Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Finance Lease, Right-of-Use Asset, after Accumulated Amortization Finance Lease, Right-of-Use Asset, after Accumulated Amortization Equity Component [Domain] Equity Component [Domain] Reconciliation of cash and cash equivalents, and restricted cash, end of period: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Statement [Table] Statement [Table] Interest expense (including amounts with related parties) Interest expense on related-party notes payable Interest Expense, Debt Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency Measurement Frequency [Domain] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Financial Statement Details [Line Items] Financial Statement Details [Line Items] Financial Statement Details [Line Items] NantBio NantBio Inc [Member] Nant Bio. Common stock, value available for future stock issuance Common Stock Value Available For Future Stock Issuance Common stock value available for future stock issuance. Interest Interest Paid, Excluding Capitalized Interest, Operating Activities $505 Million Promissory Note, December 2024 $505 Million Promissory Note, December 2024 [Member] $505 Million Promissory Note, December 2024 Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Derivative Liabilities Derivatives, Embedded Derivatives [Policy Text Block] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Supplemental disclosure of non-cash activities: Noncash Investing and Financing Items [Abstract] Income Taxes Income Tax Disclosure [Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Noncurrent Liabilities Other Noncurrent Liabilities [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Embedded contingent derivative liability related to Second Payment Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Revenue Interest Liability Debt, Policy [Policy Text Block] Weighted average discount rate, operating leases Operating Lease, Weighted Average Discount Rate, Percent Christobel Selecky [Member] Christobel Selecky Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Reportable Segment Reportable Segment [Member] Reportable Segment Initial Payment Initial Payment [Member] Initial Payment Fair value, beginning balance Fair value, ending balance Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Affiliated Entity Affiliated Entity [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Geographical Geographical [Domain] Summary of Disaggregated Revenue Disaggregation of Revenue [Table Text Block] Issuance of common stock "at the market" offering, net of commissions and offering costs Stock Issued During Period, Value, New Issues Collaboration Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Prepayment and accrued interest upon specified transaction Debt Instrument, Prepayment And Accrued Interest Debt Instrument, Prepayment And Accrued Interest Summary of Stock-Based Compensation Expense Included on Statements of Operations Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Summary of Revenue Interest Liability Activity Summarizes the Revenue Interest Liability Activity [Table Text Block] Summarizes the Revenue Interest Liability Activity Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.0001 par value; 1,350,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 915,625,053 and 852,904,340 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively; excluding treasury stock, 163,800 shares outstanding as of June 30, 2025 and December 31, 2024 Common Stock, Value, Issued Operating cash flow from finance leases Finance Lease, Interest Payment on Liability Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Initial and Expansion Premises Initial And Expansion Premises [Member] Initial And Expansion Premises Within 12 Months of Closing Date Period One [Member] Period One Accounting Policies [Table] Accounting Policies [Table] Accounting policies. Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Fair Value by Liability Class Fair Value by Liability Class [Domain] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] $30 Million March 2023 Promissory Note $30 Million March 2023 Promissory Note [Member] $30 Million March 2023 Promissory Note Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] $505 Million Promissory Note, December 2023, Tranche 1 $505 Million Promissory Note, December 2023, Tranche 1 [Member] $505 Million Promissory Note, December 2023, Tranche 1 Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Net loss per ImmunityBio common share – basic (in dollars per share) Earnings Per Share, Basic Related Party Notes Related Party Notes [Member] Related Party Notes Proceeds from equity offerings, net of discounts and issuance costs Proceeds from Issuance of Common Stock Cash paid for operating leases (excluding variable lease costs) Operating Lease, Payments Finance lease costs (including right-of-use asset amortization and interest expense) Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense Cash and cash equivalents Cash and Cash Equivalents [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Contractual Obligation Contractual Obligation Ownership Ownership [Domain] Personnel-related costs Research and Development Expense, Internal, Personnel-related Costs Research and Development Expense, Internal, Personnel-related Costs Property and equipment purchases included in accounts payable, accrued expenses and other liabilities, and due to related parties Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Embedded Derivative Financial Instruments Embedded Derivative Financial Instruments [Member] Property, Plant and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Total definite-lived intangible assets Finite-Lived Intangible Assets, Net [Abstract] Total current liabilities Liabilities, Current Unrecognized compensation cost related to unvested stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Concentration of Major Customers, Credit Risk, and Other Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Granted (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Commitment to hire, number of employees, first two and a half years Leasehold Interest, Commitment to Hire, Number of Employees, First Two and a Half Years Leasehold Interest, Commitment to Hire, Number of Employees, First Two and a Half Years Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Asset Acquisitions and Business Combinations Business Combinations Policy [Policy Text Block] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Revenue Recognition, Milestone Method [Line Items] Revenue Recognition, Milestone Method [Line Items] Fair Value of Warrants, Carrying Amount [Roll Forward] Fair Value of Warrants, Carrying Amount [Roll Forward] Fair Value of Warrants, Carrying Amount Exercise price of warrants (in dollars per share) Exercise price of warrants exercised (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Total revenue Total segment revenue Revenues Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Expansion of licensed premises (in square feet) Increase to Number of Square Foot of Facility Leased Increase to Number of Square Foot of Facility Leased Entity Address, City or Town Entity Address, City or Town Insurance premium financing asset Insurance Premium Financing Asset Insurance premium financing asset. Lease Obligations Lessee, Leases [Policy Text Block] Summary of Stock Option Activity under Equity Plans Share-Based Payment Arrangement, Option, Activity [Table Text Block] Aggregate intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Stock-based compensation expense Share-Based Payment Arrangement, Expense Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] 3M IPC and Access to Advanced Health Institute License Agreement 3M IPC and AAHI Agreement [Member] 3M IPC and AAHI Agreement Conversion of convertible promissory notes Stock Issued During Period, Value, Conversion of Convertible Securities Second Payment Second Payment [Member] Second Payment Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Other Commitments [Table] Other Commitments [Table] Forfeited/canceled (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition Business Acquisition [Axis] Total area of real estate property Area of Real Estate Property Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Finance Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Milestone payment, amount Collaboration Agreements, Milestone Payment, Amount Collaboration Agreements, Milestone Payment, Amount Revenues Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Assets measured at fair value Assets, Fair Value Disclosure Other Other Accrued Liabilities, Current 2025 (excluding the six months ended June 30, 2025) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2030 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock Sale of Stock [Axis] Derivative liabilities (Note 13) Embedded derivative liability Embedded Derivative, Fair Value of Embedded Derivative Liability Finance Lease, Liability, Current Finance Lease, Liability, Current Finished goods Inventory, Finished Goods, Net of Reserves Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Dr. Soon-Shiong and Related Party Dr Soon-Shiong And Related Party [Member] Dr. Soon-Shiong and related party. Nonvested, beginning balance (in units) Nonvested, ending balance (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Asset Class Asset Class [Axis] Insider Trading Arrangements [Line Items] Net unrealized (losses) gains on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Current Assets Other Current Assets [Member] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three Revenue recognized Contract with Customer, Liability, Revenue Recognized Prepaid expenses and other current assets Prepaid expenses and other current assets (including amounts with related parties) Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Measurement input Embedded Derivative Liability, Measurement Input Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] July 2019 Lease July Twenty Nineteen Lease [Member] July twenty nineteen lease. Exercise price per share Measurement Input, Exercise Price [Member] Outstanding RSUs RSUs Restricted Stock Units (RSUs) [Member] Noncontrolling Interests Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Increase (Decrease) in Statements of Stockholders’ Deficit [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Prepaid expenses Prepaid Expense Loss on litigation settlement Litigation Settlement, Loss Income Statement Location Statement of Income Location, Balance [Domain] Purchases of marketable debt securities, available-for-sale Payments to Acquire Debt Securities, Available-for-Sale Company Selected Measure Name Company Selected Measure Name